WO2008070308A3 - Method and composition of a carminative herb or natural supplement to decrease the adverse effects of orlistat, an oral lipase inhibitor, and a method with formulations to concurrently reduce fracture risk and insure appropriate fatsoluble vitamin supplementation when using orlistat, an oral lipase inhibitor, and a method o - Google Patents

Method and composition of a carminative herb or natural supplement to decrease the adverse effects of orlistat, an oral lipase inhibitor, and a method with formulations to concurrently reduce fracture risk and insure appropriate fatsoluble vitamin supplementation when using orlistat, an oral lipase inhibitor, and a method o Download PDF

Info

Publication number
WO2008070308A3
WO2008070308A3 PCT/US2007/082062 US2007082062W WO2008070308A3 WO 2008070308 A3 WO2008070308 A3 WO 2008070308A3 US 2007082062 W US2007082062 W US 2007082062W WO 2008070308 A3 WO2008070308 A3 WO 2008070308A3
Authority
WO
WIPO (PCT)
Prior art keywords
orlistat
lipase inhibitor
oral lipase
oral
carminative
Prior art date
Application number
PCT/US2007/082062
Other languages
French (fr)
Other versions
WO2008070308A2 (en
Inventor
Md Ronald J Thompson
Original Assignee
Md Ronald J Thompson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/585,633 external-priority patent/US20080069906A1/en
Priority claimed from US11/602,935 external-priority patent/US20080119540A1/en
Priority claimed from US11/796,982 external-priority patent/US20080070845A1/en
Application filed by Md Ronald J Thompson filed Critical Md Ronald J Thompson
Publication of WO2008070308A2 publication Critical patent/WO2008070308A2/en
Publication of WO2008070308A3 publication Critical patent/WO2008070308A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/282—Artemisia, e.g. wormwood or sagebrush
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537—Salvia (sage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/84—Valerianaceae (Valerian family), e.g. valerian
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)

Abstract

A medicament to decrease the adverse events of Orlistat, an oral lipase inhibitor, arranged to be taken in combination with Orlistat, comprising: an admixture of carminative herbs and one or more chelating agents to absorb and mechanically agitate non-digested fats. Orlistat, being an oral lipase inhibitor, blocks the absorption of ingested fats from the small intestines, to enable proven weight loss. Fat-soluble vitamin deficiencies can be a consequence of orlistat use, especially if used for a long time without medical supervision. The present invention comprises a fat-soluble-only vitamin complex, specifically for use with orlistat, which vitamin complex contains a significantly increased amount of vitamin D, to prevent osteoporosis and to reduce fracture risk. A method of using orlistat for reducing ghrelin levels in a human body to facilitate weight reduction and to permanently reduce appetite and eliminate weight regain by the step of orally ingesting tetrahydrolipstatin - THL (Orlistat) on a regular basis for a period of at least one to two years.
PCT/US2007/082062 2006-10-24 2007-10-22 Method and composition of a carminative herb or natural supplement to decrease the adverse effects of orlistat, an oral lipase inhibitor, and a method with formulations to concurrently reduce fracture risk and insure appropriate fatsoluble vitamin supplementation when using orlistat, an oral lipase inhibitor, and a method o WO2008070308A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US11/585,633 US20080069906A1 (en) 2006-09-18 2006-10-24 Method and composition of a carminative herb or natural supplement to decrease the adverse effects of orlistat, and oral lipase inhibitor
US11/585,633 2006-10-24
US11/602,935 2006-11-21
US11/602,935 US20080119540A1 (en) 2006-11-21 2006-11-21 Method of using oral lipase inhibitors to reduce plasma ghrelin and to prevent weight regain
US11/796,982 2007-04-30
US11/796,982 US20080070845A1 (en) 2006-09-18 2007-04-30 Method and formulations to concurrently reduce fracture risk and insure appropriate fat-soluble vitamin supplementation when using Orlistat, an oral lipase inhibitor

Publications (2)

Publication Number Publication Date
WO2008070308A2 WO2008070308A2 (en) 2008-06-12
WO2008070308A3 true WO2008070308A3 (en) 2008-11-20

Family

ID=39492921

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/082062 WO2008070308A2 (en) 2006-10-24 2007-10-22 Method and composition of a carminative herb or natural supplement to decrease the adverse effects of orlistat, an oral lipase inhibitor, and a method with formulations to concurrently reduce fracture risk and insure appropriate fatsoluble vitamin supplementation when using orlistat, an oral lipase inhibitor, and a method o

Country Status (1)

Country Link
WO (1) WO2008070308A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017019480A2 (en) * 2015-03-18 2018-05-22 Callion Pharma, Llc unit dosage of expandable vitamin composition, and method for treating a fat-soluble vitamin deficiency.

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237118A (en) * 1972-03-06 1980-12-02 Howard Alan N Dietary supplement and dietary methods employing said supplement for the treatment of obesity
US4246893A (en) * 1978-07-05 1981-01-27 Daniel Berson Inflatable gastric device for treating obesity
JPH1129485A (en) * 1997-07-10 1999-02-02 Kureha Chem Ind Co Ltd Antiobestic medicine
US6022718A (en) * 1998-07-02 2000-02-08 Maruzen Pharmaceuticals Co., Ltd. Method of producing capsaicin analogues
JP2003026585A (en) * 2001-07-10 2003-01-29 Maruzen Pharmaceut Co Ltd Lipase inhibitor
US20040105838A1 (en) * 2000-07-28 2004-06-03 Pierre Barbier Orlistat compositions
US20060229261A1 (en) * 2005-04-12 2006-10-12 John Devane Acarbose methods and formulations for treating chronic constipation
US20060258620A1 (en) * 2002-04-17 2006-11-16 Burnham Institute For Medical Research Novel method for the asymmetric synthesis of beta-lactone compounds

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237118A (en) * 1972-03-06 1980-12-02 Howard Alan N Dietary supplement and dietary methods employing said supplement for the treatment of obesity
US4246893A (en) * 1978-07-05 1981-01-27 Daniel Berson Inflatable gastric device for treating obesity
JPH1129485A (en) * 1997-07-10 1999-02-02 Kureha Chem Ind Co Ltd Antiobestic medicine
US6022718A (en) * 1998-07-02 2000-02-08 Maruzen Pharmaceuticals Co., Ltd. Method of producing capsaicin analogues
US20040105838A1 (en) * 2000-07-28 2004-06-03 Pierre Barbier Orlistat compositions
JP2003026585A (en) * 2001-07-10 2003-01-29 Maruzen Pharmaceut Co Ltd Lipase inhibitor
US20060258620A1 (en) * 2002-04-17 2006-11-16 Burnham Institute For Medical Research Novel method for the asymmetric synthesis of beta-lactone compounds
US20060229261A1 (en) * 2005-04-12 2006-10-12 John Devane Acarbose methods and formulations for treating chronic constipation

Also Published As

Publication number Publication date
WO2008070308A2 (en) 2008-06-12

Similar Documents

Publication Publication Date Title
RU2334523C2 (en) Composition for treatment of obesity and associated metabolic syndrome
WO2007018588A8 (en) Stable pharmaceutical composition comprising linezolid form iv
WO2009032888A3 (en) Method for providing energy, relieving stress and mood enhancing benefits comprising administering a composition comprising cholecalciferol and a tea extract
WO2008040534A3 (en) Non-mucoadhesive film dosage forms
GEP20156281B (en) Orally administered corticosteroid compositions
WO2009152189A8 (en) Low dose topiramate/phentermine compostion and methods of use thereof
WO2007012022A3 (en) Unit dose form with ibuprofen-famotidine admixture
MX347237B (en) Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction.
WO2007002836A3 (en) Methods and compositions for the prevention and treatment of kidney disease
DE602007010018D1 (en) PHARMACEUTICAL COMPOSITION CONTAINING CORDYCEPIN FOR THE TREATMENT AND PREVENTION OF FAT
IL196425A0 (en) Pharmaceutical compositions containing ibuprofen and famotidine
WO2007136845A3 (en) Low-dose doxepin for treatment of sleep disorders in elderly patients
WO2008112773A3 (en) Droxidopa and pharmaceutical composition thereof for the treatment of neurally mediated hypotension
WO2004020403A3 (en) A composition and method to augment and sustain neurotransmitter production
WO2007106968A1 (en) Compositions and methods for increasing metabolism, thermogenesis and/or muscular definition
NZ598370A (en) Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week at unit dose of 100 to 200 units
WO2011044523A3 (en) Compositions and methods for treating obesity
WO2007081486A3 (en) Oral administration of defensins to treat intestinal diseases
US7943183B2 (en) Compositions and methods for increasing metabolism, thermogenesis and/or muscular definition
TW200735863A (en) Dietary compositions for enhancing metabolism and reducing reactive oxygen species
WO2005120518A3 (en) Use of atp analogues for treatment of cardiovascular diseases
WO2008070308A3 (en) Method and composition of a carminative herb or natural supplement to decrease the adverse effects of orlistat, an oral lipase inhibitor, and a method with formulations to concurrently reduce fracture risk and insure appropriate fatsoluble vitamin supplementation when using orlistat, an oral lipase inhibitor, and a method o
WO2010079910A3 (en) Eyesight-protecting composition containing functional components having preventive and therapeutic efficacy in diabetes or diabetes complications
WO2010023572A4 (en) Herbal extract as sensitivity enhancer toward insulin and antidiabetes
MD20060037A (en) Method of treating the acute viral hepatitis C

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07871200

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07871200

Country of ref document: EP

Kind code of ref document: A2